Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2021 | Myeloma: BCMA loss as an escape mechanism

Mehmet Samur • 6 May 2021
IMS 2021
Multiple Myeloma Antibodies CAR-T

B-cell maturation antigen (BCMA) has become a widely used therapeutic target in multiple myeloma, with three major forms of treatment including antibody–drug conjugates (ADCs), bispecific T-cell engagers (BITEs), and chimeric antigen receptor (CAR) T-cell therapies. In this video, Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, talks on BCMA loss as an escape mechanism. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.

More from Mehmet Samur

Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more 13:45
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
Francesco Maura et al. • 24 Oct 2025
Highlights from a session on advances in myeloma biology at COMy 2025 2:45
Highlights from a session on advances in myeloma biology at COMy 2025
Mehmet Samur • 19 May 2025
The value of whole genome sequencing in multiple myeloma 1:53
The value of whole genome sequencing in multiple myeloma
Mehmet Samur • 19 May 2025
Advancing the understanding of the biology of extramedullary disease in myeloma 2:24
Advancing the understanding of the biology of extramedullary disease in myeloma
Mehmet Samur • 19 May 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals